STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.

Conclusions: The bifunctional, immunostimulatory, and tolerance-breaking design of CpG-STAT3ASO offers a blueprint for the development of effective and safer oligonucleotide strategies for treatment of immunologically "cold" human cancers. Clin Cancer Res; 1-15. ©2018 AACR. PMID: 30337279 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2S3qy3C